Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Introduction There has been a dramatic shift in the treatment of advanced cutaneous melanoma within the last 5 years. Until 2011, the only FDA-approved therapies for metastatic melanoma were dacarbazine chemotherapy or high-dose interleukin-2 (IL-2) immunotherapy, which each have limited…
Key Points Surgical resection should be considered for all patients with limited numbers of metastatic sites. Standard cytotoxic chemotherapy has limited efficacy in metastatic melanoma, with response rates in the 10–20% range and short-lived response durations. High-dose IL-2 is associated…